专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明授权

US09365512B2 Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy 有权
标题翻译：异二氢吲哚衍生物，含有它们的药物组合物及其在治疗中的应用
公开(公告)号：US09365512B2
公开(公告)日：2016-06-14
申请号：US13764454
申请日：2013-02-11
申请人： AbbVie Deutschland GmbH & Co. KG , AbbVie Inc.
发明人： Wilhelm Amberg , Udo Lange , Michael Ochse , Frauke Pohlki , Charles W. Hutchins , Irini Zanze , Hongyu H. Zhao , Huan-Qiu Li , Ying X. Wang
IPC分类号： C07D403/12 , C07D209/46 , C07D405/14 , C07D209/44
CPC分类号： C07D209/46 , C07D209/44 , C07D403/12 , C07D405/14
摘要： The present invention relates to isoindoline derivatives of the formula (I) or a physiologically tolerated salt thereof. The present invention also relates to pharmaceutical compositions comprising such isoindoline derivatives, and the use of such isoindoline derivatives for therapeutic purposes.
摘要翻译：本发明涉及式（I）的异二氢吲哚衍生物或其生理上耐受的盐。本发明还涉及包含这种异二氢吲哚衍生物的药物组合物，以及用于治疗目的的这种异吲哚啉衍生物的用途。

22. 发明授权

US09200005B2 Inhibitor compounds of phosphodiesterase type 10A 有权
标题翻译：磷酸二酯酶10A型抑制剂化合物
公开(公告)号：US09200005B2
公开(公告)日：2015-12-01
申请号：US14189961
申请日：2014-02-25
申请人： AbbVie Deutschland GmbH & Co. KG , AbbVie Inc.
发明人： Katja Jantos , Michael Ochse , Hervé Geneste , Jayne Froggett , Clarissa Jakob , Karla Drescher , Jürgen Dinges
IPC分类号： C07D495/04
CPC分类号： C07D495/04
摘要： The present invention relates to compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof: In formula I the variables X1 is CH or N, X2 is O or S and where R1, R2, R3, R4 and Q are as defined in the claims.The compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof are inhibitors of phosphodiesterase type 10A. Thus, the invention also relates to the use of the compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
摘要翻译：本发明涉及式I化合物，N-氧化物，互变异构体，其前药及其药学上可接受的盐：在式I中，变量X1是CH或N，X2是O或S，并且其中R1，R2，R3 R4和Q如权利要求中所定义。式I化合物，N-氧化物，互变异构体，其前药和药学上可接受的盐是10A型磷酸二酯酶的抑制剂。因此，本发明还涉及式I化合物，N-氧化物，互变异构体，前药和其药学上可接受的盐在制备药物中的用途，因此其适用于治疗或控制医学病症选自神经障碍和精神障碍，用于改善与这种障碍相关的症状并降低这种障碍的风险。

23. 发明申请

US20220169620A1 SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS 有权
公开(公告)号：US20220169620A1
公开(公告)日：2022-06-02
申请号：US17537600
申请日：2021-11-30
申请人： AbbVie Deutschland GmbH & Co. KG
发明人： Willie Amberg , Gisela Backfisch , Karen Bodié , Katja Hempel , Loic Laplanche , Mario Mezler , Michael Ochse , Sean Turner , Jeroen van Bergeijk , Elizabeth van der Kam
IPC分类号： C07D265/34
摘要： The present invention is directed to spiro-cyclic amine derivatives which are modulators of S1P receptors and are useful in the treatment of CNS disorders.

24. 发明申请

US20170174672A1 FUSED (HETERO)CYCLIC COMPOUNDS AS S1P MODULATORS 审中-公开
公开(公告)号：US20170174672A1
公开(公告)日：2017-06-22
申请号：US15388516
申请日：2016-12-22
申请人： AbbVie Deutschland GmbH & Co. KG
发明人： Wilhelm Amberg , Udo Lange , Herve Geneste , Michael Ochse , Ralf Biesinger , Frank Oellien
IPC分类号： C07D413/12 , C07D205/04 , C07C229/48 , C07C229/46 , C07D211/62 , C07D261/12 , C07D209/52 , C07D207/16 , C07D207/08 , C07D265/36 , C07C59/72 , C07D405/04 , C07D311/04
CPC分类号： C07D413/12 , C07C59/72 , C07C229/30 , C07C229/36 , C07C229/46 , C07C229/48 , C07C229/50 , C07C2601/04 , C07C2601/14 , C07C2602/10 , C07C2602/38 , C07D205/04 , C07D207/06 , C07D207/08 , C07D207/16 , C07D209/52 , C07D209/94 , C07D211/32 , C07D211/62 , C07D261/12 , C07D265/36 , C07D265/38 , C07D311/04 , C07D311/58 , C07D405/04 , C07D405/14
摘要： The invention relates to (hetero)cyclic compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.

25. 发明申请

US20150183770A1 5-RING HETEROAROMATIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS 审中-公开
标题翻译： 5环异构体化合物及其作为5-HT5受体的结合合作伙伴使用
公开(公告)号：US20150183770A1
公开(公告)日：2015-07-02
申请号：US14584902
申请日：2014-12-29
申请人： ABBVIE DEUTSCHLAND GMBH & CO. KG
发明人： Wilhelm Amberg , Astrid Netz , Andreas Kling , Michael Ochse , Udo Lange , Andreas Haupt , Francisco Javier Garcia-Ladona , Wolfgang Wernet (Deceased)
IPC分类号： C07D417/04 , C07D231/38 , C07D405/04 , C07D409/04 , C07D413/04 , C07D233/88 , C07D249/14
CPC分类号： C07D417/04 , C07D231/38 , C07D233/70 , C07D233/88 , C07D249/14 , C07D405/04 , C07D409/04 , C07D413/04
摘要： The invention relates to 5-ring heteroaromatic compounds of general formula (I), their use for the treatment and/or prevention of diseases, and medicaments containing same.
摘要翻译：本发明涉及通式（I）的5-环杂芳族化合物，其用于治疗和/或预防疾病的用途，以及含有它们的药物。

26. 发明授权

US09475782B2 Guanidine compounds, and use thereof as binding partners for 5-HT5 receptors 有权
公开(公告)号：US09475782B2
公开(公告)日：2016-10-25
申请号：US13683296
申请日：2012-11-21
申请人： AbbVie Deutschland GmbH & Co. KG
发明人： Astrid Netz , Wilhelm Amberg , Udo Lange , Michael Ochse , Charles W. Hutchins , Francisco-Xavier Garcia-Ladona , Wolfgang Wernet , Andreas Kling
IPC分类号： C07D277/48 , C07D277/82 , C07D333/36 , C07D263/48 , C07D277/60 , C07D235/30 , C07D513/04 , C07D417/12 , C07D417/04 , C07D231/56 , C07D237/22 , C07D249/14 , C07D261/14 , C07D263/28 , C07D285/08 , C07D285/135
CPC分类号： C07D277/48 , C07D231/56 , C07D235/30 , C07D237/22 , C07D249/14 , C07D261/14 , C07D263/28 , C07D263/48 , C07D277/60 , C07D277/82 , C07D285/08 , C07D285/135 , C07D333/36 , C07D417/04 , C07D417/12 , C07D513/04
摘要： The present invention relates to guanidine compounds of the general formula I corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof. The present compound further relates to the use of guanidine compounds as binding partners for 5-HT5 receptors for the treatment of diseases which are modulated by a 5-HT5 receptor activity, in particular for the treatment of neurodegenerative and neuropsychiatric disorders as well as the associated signs, symptoms and dysfunctions.

27. 发明授权

US09227930B2 Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy 有权
标题翻译：氨基茚满衍生物，含有它们的药物组合物及其在治疗中的应用
公开(公告)号：US09227930B2
公开(公告)日：2016-01-05
申请号：US14317104
申请日：2014-06-27
申请人： ABBOTT LABORATORIES , ABBVIE DEUTSCHLAND GMBH & CO KG
发明人： Frauke Pohlki , Udo Lange , Wilhelm Amberg , Michael Ochse , Berthold Behl , Charles W. Hutchins
IPC分类号： A61K31/135 , C07C211/27 , C07C311/14 , C07C311/10 , C07D205/04 , C07D231/18 , C07D403/12 , C07D233/84
CPC分类号： C07C311/14 , C07C311/10 , C07C2601/02 , C07C2602/08 , C07D205/04 , C07D231/18 , C07D233/84 , C07D403/12
摘要： The present invention relates to aminoindane derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such aminoindane derivatives, and the use of such aminoindane derivatives for therapeutic purposes. The aminoindane derivatives are GlyT1 inhibitors.
摘要翻译：本发明涉及式（I）的氨基茚满衍生物或其生理上耐受的盐。本发明涉及包含这种氨基茚满衍生物的药物组合物以及这种氨基茚满衍生物用于治疗目的的用途。氨基茚满衍生物是GlyT1抑制剂。

28. 发明授权

US09067871B2 Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy 有权
公开(公告)号：US09067871B2
公开(公告)日：2015-06-30
申请号：US14031265
申请日：2013-09-19
申请人： ABBVIE DEUTSCHLAND GMBH & CO KG , ABBOTT LABORATORIES
发明人： Wilhelm Amberg , Michael Ochse , Udo Lange , Andreas Kling , Berthold Behl , Wilfried Hornberger , Mario Mezler , Charles W. Hutchins
IPC分类号： A61K31/16 , C07C215/70 , C07C311/05 , C07C215/64 , C07C217/74 , C07C233/18 , C07C233/19 , C07C233/69 , C07C255/58 , C07C271/24 , C07C307/06 , C07C309/65 , C07C311/07 , C07C311/09 , C07C311/10 , C07C311/14 , C07C311/17 , C07C311/18 , C07C311/20 , C07C311/24 , C07C317/18 , C07C317/28 , C07D205/04 , C07D207/10 , C07D207/12 , C07D207/27 , C07D207/36 , C07D207/48 , C07D213/71 , C07D231/18 , C07D233/84 , C07D249/12 , C07D261/08 , C07D275/02 , C07D295/096 , C07D305/08 , C07D333/34 , C07D403/12 , C07F7/08 , C07D401/12 , C07D409/12
CPC分类号： C07C311/05 , C07C215/64 , C07C217/74 , C07C233/18 , C07C233/19 , C07C233/69 , C07C255/58 , C07C271/24 , C07C307/06 , C07C309/65 , C07C311/07 , C07C311/09 , C07C311/10 , C07C311/13 , C07C311/14 , C07C311/17 , C07C311/18 , C07C311/20 , C07C311/24 , C07C317/18 , C07C317/28 , C07C2601/02 , C07C2601/04 , C07C2602/10 , C07D205/04 , C07D207/09 , C07D207/10 , C07D207/12 , C07D207/27 , C07D207/36 , C07D207/48 , C07D213/71 , C07D231/18 , C07D233/84 , C07D249/12 , C07D261/08 , C07D265/30 , C07D275/02 , C07D295/096 , C07D295/135 , C07D305/08 , C07D333/34 , C07D401/12 , C07D403/12 , C07D409/12 , C07F7/081
摘要： The present invention relates to aminotetraline derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such aminotetraline derivatives, and the use of such aminotetraline derivatives for therapeutic purposes. The aminotetraline derivatives are GlyT1 inhibitors.

29. 发明授权

US09238619B2 Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy 有权
标题翻译：苯烷基胺衍生物，含有它们的药物组合物及其在治疗中的用途
公开(公告)号：US09238619B2
公开(公告)日：2016-01-19
申请号：US14282712
申请日：2014-05-20
申请人： AbbVie Deutschland GmbH & Co. KG , Abbott Laboratories
发明人： Frauke Pohlki , Udo Lange , Wilhelm Amberg , Michael Ochse , Berthold Behl , Wilfried Hornberger , Mario Mezler , Charles W. Hutchins , Sean Turner
IPC分类号： A61K31/135 , C07C211/25 , C07C311/06 , C07C311/04 , C07C311/05 , C07C311/10 , C07D205/04 , C07D207/08 , C07D207/267 , C07D231/18 , C07D233/42 , C07D295/135 , C07D401/12 , C07D403/12 , C07D233/84
CPC分类号： C07C311/06 , C07C311/04 , C07C311/05 , C07C311/10 , C07C2601/02 , C07C2601/04 , C07D205/04 , C07D207/08 , C07D207/267 , C07D231/18 , C07D233/42 , C07D233/84 , C07D295/135 , C07D401/12 , C07D403/12
摘要： The present invention relates to phenalkylamine derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such phenalkylamine derivatives, and the use of such phenalkylamine derivatives for therapeutic purposes. The phenalkylamine derivatives are GlyT1 inhibitors.
摘要翻译：本发明涉及式（I）的苯烷基胺衍生物或其生理上耐受的盐。本发明涉及包含这种苯烷基胺衍生物的药物组合物，以及这种苯烷基胺衍生物用于治疗目的的用途。酚烷基胺衍生物是GlyT1抑制剂。

30. 发明申请

US20140309206A1 AMINOINDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY 有权
标题翻译：氨基丹衍生物，含有它们的药物组合物及其在治疗中的使用
公开(公告)号：US20140309206A1
公开(公告)日：2014-10-16
申请号：US14317104
申请日：2014-06-27
申请人： ABBOTT LABORATORIES , ABBVIE DEUTSCHLAND GMBH & CO KG
发明人： Frauke Pohlki , Udo Lange , Wilhelm Amberg , Michael Ochse , Berthold Behl , Charles W. Hutchins
IPC分类号： C07C311/14 , C07D231/18 , C07D205/04 , C07D403/12 , C07C311/10 , C07D233/84
CPC分类号： C07C311/14 , C07C311/10 , C07C2601/02 , C07C2602/08 , C07D205/04 , C07D231/18 , C07D233/84 , C07D403/12
摘要： The present invention relates to aminoindane derivatives of the formula (I) or a physiologically tolerated salt thereof.The invention relates to pharmaceutical compositions comprising such aminoindane derivatives, and the use of such aminoindane derivatives for therapeutic purposes. The aminoindane derivatives are GlyT1 inhibitors.
摘要翻译：本发明涉及式（I）的氨基茚满衍生物或其生理上耐受的盐。本发明涉及包含这种氨基茚满衍生物的药物组合物以及这种氨基茚满衍生物用于治疗目的的用途。氨基茚满衍生物是GlyT1抑制剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式